Diabetic Peripheral Neuropathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Diabetic Peripheral Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions.
Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs
and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet; pain or
discomfort in the feet or legs, including prickly, sharp pain or burning feet; muscle weakness and loss of muscle tone
in the feet and lower leg; loss of balance; dry feet; and cracked skin. The predisposing factors include diabetes,
smoking, and kidney diseases. Treatment includes antidepressants, anti-seizure drugs, and opioid analgesics.
The Diabetic Peripheral Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Diabetic Peripheral Neuropathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 31 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Diabetic Peripheral Neuropathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Diabetic Peripheral Neuropathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Diabetic Peripheral Neuropathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abalone Bio IncAchelios Therapeutics Inc
Applied Therapeutics Inc
Beijing Tide Pharmaceutical Co Ltd
Bexion Pharmaceuticals Inc
Biogen Inc
CSPC Pharmaceutical Group Ltd
Exodos Life Sciences Limited Partnership
G&P Bioscience Co Ltd
Grunenthal GmbH
Ion Channel Pharmacology LLC
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Nervosave Therapeutics
PharmAbcine Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sino Biopharmaceutical Ltd
Sonnet BioTherapeutics Holdings Inc
VCANBIO Cell and Gene Engineering Corp Ltd
Vertex Pharmaceuticals Inc
Winsantor Inc
Zhejiang Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Diabetic Peripheral Neuropathy reports